Drug is already approved in some European countries - Ireland, Sweden, Norway, Germany and U.K. Trade name is Acomplia. In USA, Acomplia is awaiting approval from FDA office /probably April 2007/.Trade mark for USA should be Rimonabant Zimulti.



Rimonabant works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System).

Human tests began in 2002 and demonstrated a significant reduction in abdominal obesity, an independent marker for heart disease.

Acomplia also improves cardiovascular/ metabolic risk factors in overweight/obese patients.

Dramatic health corections were reported in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides (bad cholesterol).

Prices of Rimonabant Acomplia are around 3 - 3.8 Euro per pill.